# Harmony Biosciences BP-205 Phase 1 SAD Data: Favorable PK and No Serious Adverse Events, Phase 1b and Phase 2 Studies Planned for 2026-2027

> news · REPORTED · 2026-08-04

Alongside Q2 2026 earnings on August 4, Harmony Biosciences disclosed that Phase 1 single ascending dose data for BP-205, its orexin-2 receptor agonist, demonstrated rapid absorption, a 25-hour half-life supporting once-daily dosing, over 600-fold selectivity for OX2R over OX1R, and no serious or severe adverse events. The company confirmed its US IND is open and Phase 1b in sleep-deprived healthy volunteers is initiating in Q3 2026.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is developing BP-205 as a potential best-in-class orexin-2 receptor agonist for multiple CNS indications including hypersomnolence disorders and ADHD, as part of a diversified rare neurological disease pipeline anchored by its commercial WAKIX franchise.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://uk.finance.yahoo.com/news/harmony-biosciences-holdings-inc-hrmy-210258211.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.